Combining Arcoxia with another NSAID increases the risk of gastrointestinal bleeding and cardiovascular events. This combination is generally discouraged unless specifically directed by a physician who will monitor for adverse effects.
Peripheral edema can be a side effect of COX-2 inhibitors. Inform your healthcare provider promptly; they may adjust the dose, switch to an alternative analgesic, or add a diuretic if appropriate.
Long-term therapy may be appropriate for some patients with osteoarthritis or rheumatoid arthritis, but it requires regular monitoring of blood pressure, renal function, and liver enzymes to mitigate risks.
In Hong Kong, the tablets are typically differentiated by color and imprint: 60 mg (white, “AR-60”), 90 mg (blue, “AR-90”), and 120 mg (pink, “AR-120”). Always verify the imprint before taking the medication.
Yes, but carry the prescription label and a copy of the prescribing doctor’s note. Some countries may require a medical certificate for controlled prescription drugs.
Moderate alcohol use does not significantly alter pain relief, but excessive drinking can increase stomach irritation and bleeding risk. Discuss your drinking habits with your clinician.
A PPI may be prescribed for patients at higher risk of gastrointestinal complications, such as those with a history of ulcers or concurrent corticosteroid use.
Arcoxia selectively inhibits COX-2, potentially offering similar pain relief with less gastric irritation compared to non-selective NSAIDs that block both COX-1 and COX-2. However, COX-2 inhibitors may carry a higher cardiovascular risk profile.
Migraine is not an approved indication for etoricoxib in Hong Kong. Off-label use should only be considered after specialist evaluation, weighing potential benefits against cardiovascular risks.
Arcoxia is a prescription medication that contains etoricoxib as its active component. Etoricoxib belongs to the class of selective cyclo-oxygenase-2 (COX-2) inhibitors, a subgroup of non-steroidal anti-inflammatory drugs (NSAIDs) used for pain relief. In Hong Kong, Arcoxia is classified as a prescription-only medicine and is regulated by the Hong Kong Department of Health and the Pharmacy and Poisons Board. The product is supplied as an oral pill in three strengths: 60 mg, 90 mg, and 120 mg.
Etoricoxib selectively blocks the COX-2 enzyme, which is primarily responsible for producing prostaglandins that mediate inflammation, pain, and fever. By inhibiting COX-2 while sparing COX-1, etoricoxib reduces pain and swelling with a lower risk of gastrointestinal irritation compared with non-selective NSAIDs.
Etoricoxib is absorbed quickly from the gastrointestinal tract, undergoes hepatic metabolism (primarily via CYP3A4), and is eliminated mainly in the urine and feces.
Arcoxia is approved in Hong Kong for the following indications:
These uses are based on clinical trials that demonstrated significant pain reduction compared with placebo or other NSAIDs.
When in doubt, clinicians should assess the individual’s risk-benefit profile before prescribing.
These symptoms are generally manageable and may resolve with continued therapy or dose adjustment.
Any of these signs require immediate medical attention and discontinuation of Arcoxia.
Patients should disclose all prescription drugs, over-the-counter medications, herbal products, and supplements to their healthcare provider.
Standard dosing:
60 mg once daily for mild to moderate pain or osteoarthritis.
90 mg once daily for rheumatoid arthritis, ankylosing spondylitis, or acute gout flares.
120 mg once daily may be prescribed for severe post-operative pain under close supervision.
Administration: Swallow the pill whole with a full glass of water. Do not crush or chew.
Special populations:
Renal impairment: 60 mg once daily; avoid higher doses.
Hepatic impairment: 60 mg once daily only; monitor liver enzymes.
Elderly: Start at 60 mg, assess tolerance before any increase.
Missed dose: Take the missed dose as soon as remembered unless it is near the time of the next scheduled dose; do not double up.
Overdose: Symptoms may include severe stomach pain, vomiting, or dizziness. Seek emergency medical care; supportive care is the mainstay.
Discontinuation: For chronic use, tapering is not usually required, but abrupt cessation may lead to rebound pain. Discuss any planned stop with a clinician.
If any adverse event emerges or the therapeutic goal is not achieved, the prescriber should reassess the regimen.
This article provides educational information about Arcoxia and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
